Le Lézard
Classified in: Health
Subject: ACC

Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)


LUND, Sweden, 31 May 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharmaceutical AB, approved at the Extraordinary General Meeting on 22 March 2018.

Today, the last trading day of the month, there are in total 91,570,841 shares and votes in NeuroVive Pharmaceutical AB. 

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CEST on 31 May 2018.

For more information please contact:

Daniel Schale, Director of Communications, NeuroVive

+46(0)46-275-62-21, [email protected]

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden

Tel: +46(0)46-275-62-20 (switchboard)

[email protected], www.neurovive.com

About NeuroVive 

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company's strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/neurovive-pharmaceutical/r/amended-number-of-shares-and-votes-in-neurovive-pharmaceutical-ab--publ-,c2522957

The following files are available for download:

http://mb.cision.com/Main/6574/2522957/851477.pdf

PDF

 

SOURCE NeuroVive Pharmaceutical


These press releases may also interest you

at 11:55
Global COVID-19 Vaccines Strategic Research Report 2024 - ResearchAndMarkets.com
The "COVID-19 Vaccines - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. Global COVID-19 Vaccines Market to Reach 4.2 Billion Doses by 2025 The global market for COVID-19 Vaccines, estimated at 6.4 Billion...

at 11:52
ARUP Partners With ELLKAY to Bring Connectivity Solutions to Health System Outreach Operations
ARUP Laboratories and healthcare connectivity company ELLKAY have forged a new partnership aimed at helping health systems establish or expand successful laboratory outreach operations....

at 11:37
Union Construction Industry Unites to Combat Substance Use Disorder and Build Mental Wellness at 4th Annual BTEA Recovery Week
According to data from the CDC, the construction industry has the highest overdose death rate across all industries1. Construction workers are five times more likely to die by suicide than safety-related issues2. BTEA is uniting the union...

at 11:35
A2 Bio to Highlight Progress of CAR T Clinical Programs in Three Poster Presentations at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
A2 Biotherapeutics, Inc. (A2 Bio) a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies to selectively target tumor cells and protect normal cells, today announced the acceptance of three posters for presentation...

at 11:28
New England's Premier Oral Surgery Practice Joins Qualitas Dental Partners
Qualitas Dental Partners proudly announces its partnership with the foremost oral surgery group in New England, furthering its commitment to deliver patient-centric dental care across the region....

at 11:25
MAKO Medical Partners with Rebuilding Together to Restore Home for U.S. Military Veteran
MAKO Medical, a leader in healthcare diagnostics and laboratory services, is honored to announce its partnership with Rebuilding Together, a renowned nonprofit organization focused on repairing homes, revitalizing communities, and rebuilding lives....

More news about Health...


News published on and distributed by: